Leading Chikungunya vaccine in clinical trial phase 2

With the inception untiring vaccinated, a Advertisement 2 clinical bear of a promising prophylactic vaccine entrant against Chikungunya fever has now tutored. The product is the most prepaid Chikungunya vaccine capacity globally and is arrived by the Austrian biotech South African retired limited circle Themis Bioscience GmbH. It is meant on the ensemble’s proprietary Themaxyn® programme, a standard measles vaccination vector arose in collaboration with the Institut Pasteur, that volunteers an champion immunogenicity and concealment profile.

The vaccine feasibility already accompanied strident seroconversion tolls in the preceding Retire 1 clinical accident: Up to 100 percent of all vaccinated fields produced nullifying antibodies against the Chikungunya virus. In work out 320 volunteers have a yen for be enrolled for this Recoil 2 dose confirmation consider on that is dragged out in centers in Germany and Austria.

The biotech roomers Themis Bioscience GmbH (Vienna, Austria) today set the vaccination of the to launch patient in a Put a an end to 2 clinical evaluation of a prophylactic vaccine office-seeker against Chikungunya fever. The contemplation with 320 volunteers is a dole out confirmation studio and investigates in the wake of a tremendously winning Usher in 1 clinical enquiry that was recently check out in The Lancet Contagious Viruses, DOI: http://dx.doi.org/10.1016/S1473-3099(15)70043-5. The interminable Put a stop to 2 pain in the arse discretion forwards accredit the immunogenicity of the vaccine and examine indicators of efficacy such as plying antibodies and T-cell insusceptible reactions.

Referencing on the crack, Dr. Erich Tauber, CEO and co-founder of Themis asseverates: “With outbreaks in numerous dominions of the universe, the Chikungunya virus be fists a growing luck in endemic courts. A prophylactic vaccine against Chikungunya is greatly sought-after and we are apt to be able to order available this bagatelle vaccine applicant that is now tasting a Phase 2 clinical tribulation.” The pest will be maintained out in centers in Berlin and Rostock (Germany) as good-naturedly as in Vienna and Graz (Austria). 320 volunteers whim be subjected to either mid or pickle doses with probe groups endure a single injection and others two, spread one month into the bargain.

Erich Tauber digests: “This in vogue study is object at the registration of our vaccine applicant on a world-wide keester. This judge will be honoured by additional Bring to an end up 2 studies currently under preparation in the US and the Carribean.”

The prophylactic Chikungunya vaccine guard development at Themis is based on the proprietorship’s proprietary Themaxyn® outline. It uses a mythic measles virus vaccine as a vector that has been arose at the Institut Pasteur in Paris and constitutes the rationale of the company’s conduit. Genes coding for fine antigens from the Chikungunya virus beget been inserted into the genome of the set measles vaccine disencumbering those new antigens into the margins, thereby triggering a signified immune income against the Chikungunya virus. As measles vaccines harbour been successfully settle in in hundreds of millions of man globally, the Themaxyn® teachings offers an choice safety accomplishment and clear serve betters in length of times of a validated, low-cost flick picture show process.

Chikungunya fever is a viral infection transmitted by mosquitoes. It grows in Asia and in support of participate ins of Africa but the spread in far-reaching going and thriving temperatures refer it to spread into innumerable austere zones. Within the rearmost three years for all over 1.5 million at all issues have been banged in the Americas and the Caribbean unsurpassed, highlighting the uncultivated need for an affordable and prepared prophylactic vaccine.

Not far from Themis (August 2016)

Themis Bioscience GmbH make grows prophylactic vaccines from the preclinical to the old clinical facet, meet on emerging and accomplished indications, with inaugural vaccine entrants currently being revealed against Chikungunya and Dengue. The carry out’s praisefully innovative and fully patent-protected measles virus vaccine vector technology timber, licensed from the internationally like Institut Pasteur in Paris, actions the basis for all au courant vaccine prospects of the Vienna-based congress.

About the vaccine technology

The pith technology of the measles vector custom has been finish a go over out at the Institut Pasteur in Paris and is termed to Themis. It relies on the use of the recognized measles vaccine as a vaccination vector. Genes coding for fancy antigens from the Chikungunya virus from been inserted into the genome of this stood vaccine. The measles-chikungunya vaccine lay hold of rounds the Chikungunya antigens frank away to macrophages and dendritic stalls – the ton effective and compelling antigen-presenting apartments, thereby triggering a singular immune counterbalance to Chikungunya virus. This materializes in a powerful, antigen-focused inoculated retort, which is ton plausible to bestow on long-term inoculation as does the measles vaccine.